Cargando…
Thrombocytopenia and bleeding in myelosuppressed transfusion-dependent patients: a simulation study exploring underlying mechanisms
BACKGROUND: Hematology–oncology patients often become severely thrombocytopenic and receive prophylactic platelet transfusions when their platelet count drops below 10×10(9) platelets/L. This so-called “platelet count trigger” of 10×10(9) platelets/L is recommended because currently available eviden...
Autores principales: | Middelburg, Rutger A, Kerkhoffs, Jean-Louis H, van der Bom, Johanna G |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5903482/ https://www.ncbi.nlm.nih.gov/pubmed/29692632 http://dx.doi.org/10.2147/CLEP.S149926 |
Ejemplares similares
-
Risk factors for bleeding in haemato-oncology patients—a nested case–control study: The BITE study protocol (Bleeding In Thrombocytopenia Explained)
por: Cornelissen, Loes L, et al.
Publicado: (2020) -
Thrombocytopenia and the effect of platelet transfusions on the occurrence of intracranial hemorrhage in patients with acute leukemia – a nested case-control study
por: Cornelissen, Loes L., et al.
Publicado: (2020) -
A study protocol for a randomised controlled trial evaluating clinical effects of platelet transfusion products: the Pathogen Reduction Evaluation and Predictive Analytical Rating Score (PREPAReS) trial
por: Ypma, Paula F, et al.
Publicado: (2016) -
Lurasidone Induced Thrombocytopenia: Is it a Signal of Drug Induced Myelosuppression?
por: Rafi, Mohammad, et al.
Publicado: (2018) -
Personalization of medicine requires better observational evidence
por: Middelburg, Rutger A, et al.
Publicado: (2018)